SAFETY OF COMBINED PIRFENIDONE AND NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

被引：0
|
作者：
Flaherty, K. R. [1 ]
Fell, C. D. [2 ]
Huggins, J. T. [3 ]
Nunes, H. [4 ]
Sussman, R. [5 ]
Valenzuela, C. [6 ]
Petzinger, U. [7 ]
Stauffer, J. L. [8 ]
Gilberg, F. [9 ]
Bengus, M. [9 ]
Wijsenbeek, M. [10 ]
机构：
[1] Univ Michigan, Ann Arbor, MI USA
[2] Univ Calgary, Calgary, AB, Canada
[3] Med Univ South Carolina, Charleston, SC USA
[4] Hop Avicenne, Paris, France
[5] Atlantic Hlth Syst, Overlook Med Ctr, Summit, NJ USA
[6] Hosp Univ La Princesa, Inst Invest Princesa, Madrid, Spain
[7] Clinipace Accovion GmbH, Eschborn, Germany
[8] Genentech Inc, San Francisco, CA 94080 USA
[9] F Hoffman La Roche Ltd, Basel, Switzerland
[10] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
来源：
THORAX | 2017年 / 72卷
关键词：
D O I：
10.1136/thoraxjnl-2017-210983.453
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
M31
引用
下载
收藏
页码：A253 / A254
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
    Richeldi, Luca
    Kolb, Martin
    Jouneau, Stephane
    Wuyts, Wim A.
    Schinzel, Birgit
    Stowasser, Susanne
    Quaresma, Manuel
    Raghu, Ganesh
    BMC PULMONARY MEDICINE, 2020, 20 (01)
  • [32] SINGLE CENTRE EXPERIENCE OF SWITCHING PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS FROM PIRFENIDONE TO NINTEDANIB
    Rathnapala, A.
    Fries, A.
    Ruggiero, C.
    Ho, L. P.
    Hoyles, R. K.
    THORAX, 2016, 71 : A60 - A60
  • [33] Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA
    Noth, Imre
    Oelberg, David
    Kaul, Manika
    Conoscenti, Craig S.
    Raghu, Ganesh
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (01)
  • [34] Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
    Cameli, Paolo
    Bergantini, Laura
    D'Alessandro, Miriana
    Refini, Rosa Metella
    Pieroni, Maria
    Alonzi, Valerio
    Sestini, Piersante
    Bargagli, Elena
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [35] Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
    Marijic, Pavo
    Schwarzkopf, Larissa
    Schwettmann, Lars
    Ruhnke, Thomas
    Trudzinski, Franziska
    Kreuter, Michael
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [36] HEPATIC DISORDERS OF PIRFENIDONE OR NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) A SYSTEMATIC REVIEW
    Singla, D.
    Mahapatra, S.
    Dey, A.
    John, A.
    VALUE IN HEALTH, 2022, 25 (12) : S218 - S218
  • [37] Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
    Pavo Marijic
    Larissa Schwarzkopf
    Lars Schwettmann
    Thomas Ruhnke
    Franziska Trudzinski
    Michael Kreuter
    Respiratory Research, 22
  • [38] Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis
    Marcos Ribes, Borja
    Sancho-Chust, Jose N.
    Talens, Amparo
    Arlandis, Mar
    Herraiz, Paola
    Chiner, Eusebi
    Aznar, Teresa
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (06) : 350 - 354
  • [39] Real World Experience of Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
    Mulholland, S. A.
    Al Jbour, K.
    Steer, H.
    Gutsche, M.
    Foley, N.
    Srivastava, R.
    Sharp, C.
    Adamali, H. I.
    Barratt, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [40] Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
    Lehtonen, Siri T.
    Veijola, Anniina
    Karvonen, Henna
    Lappi-Blanco, Elisa
    Sormunen, Raija
    Korpela, Saara
    Zagai, Ulrika
    Skold, Magnus C.
    Kaarteenaho, Riitta
    RESPIRATORY RESEARCH, 2016, 17
12345